Meet the 7.3% Yield Dividend Inventory That May Soar in 2026

It has been a tricky stretch for pharmaceutical big Pfizer (PFE 1.42%). The corporate loved a vaccine windfall through the COVID-19 pandemic, however income and earnings cratered because the pandemic eased and people tailwinds stopped blowing. The inventory has tumbled, sending Pfizer’s dividend yield to a whopping 7.3%.

However Pfizer’s inventory worth lately bounced on its second-quarter earnings. Buyers have been on the lookout for a glimpse into Pfizer’s future, and there’s a lot to love as issues start to come into sight.

Right here is why Pfizer’s newfound momentum may set the inventory as much as soar in 2026.

Prudent monetary administration secures a beneficiant dividend

Pfizer’s beneficiant dividend has grow to be a giant motive why many individuals take into account proudly owning the inventory. It isn’t simple to discover a 7.3% dividend yield, and oftentimes, shares that do are yield traps with vital underlying dangers.

Whereas the market’s detrimental sentiment towards Pfizer and the corporate’s post-pandemic struggles have pushed the share worth down and the yield increased, the dividend itself is on strong footing. Administration has raised the dividend for 15 consecutive years, so dropping these pandemic-related earnings did not power a dividend lower. Moreover, the present dividend of $1.72 per share is properly under the mid-point of administration’s 2025 adjusted EPS steering of $3 per share.

In different phrases, Pfizer continues to be incomes loads of cash to afford its dividend, and is utilizing that cushion to, properly, pay down debt to enhance its stability sheet. That is prudent monetary management, and may give traders some confidence that they’ll depend on the inventory’s sturdy 7.3% yield as a pleasant baseline for the inventory’s future returns.

Is Wall Avenue sleeping on Pfizer’s progress?

It appears the broader market is cautious towards healthcare shares in the intervening time. Not solely may tariffs increase prices for drug corporations, however there may be additionally strain from the Trump administration to chop prescription drug costs for People.

Nevertheless, Pfizer appears to be more and more assured that it may navigate these headwinds and develop its enterprise. Administration lately raised its 2025 adjusted earnings steering from a variety of $2.80 to $3.00 per share to $2.90 to $3.10. The corporate has centered its progress efforts on oncology and specialty medicine, that are much less prone to face pricing strain. And that is exactly the place Pfizer is rising essentially the most; the corporate’s specialty drug gross sales are up 6% yr over yr, and oncology gross sales are up 9% via six months of 2025.

As specialty and oncology drug gross sales improve, they need to have a higher impact on Pfizer’s total progress. These two segments mixed for roughly $16.5 billion via six months of this yr. Pfizer’s major care drug gross sales, totaling $11.2 billion, are down 8% yr over yr as COVID-19 gross sales proceed to fall off. Six-month gross sales of Pfizer’s COVID-19 medicine at the moment are lower than $2 billion, so their impression on the numbers is drying up. Moreover, Pfizer’s high vendor, Eliquis, faces patent expiration however doubtless will not face generic competitors till a minimum of 2028.

Analysts solely anticipate Pfizer incomes $3.10 per share subsequent fiscal yr, however that could possibly be too conservative, given Pfizer’s momentum in oncology and specialty medicine and the ensuing enhance to this yr’s steering. It appears tariff and political considerations are weighing on short-term expectations. Should you zoom out, analysts anticipate Pfizer rising earnings at an annualized price of 9% over the subsequent three to 5 years, which appears to underline the great issues taking place within the enterprise.

The circumstances are ripe for a dramatic sentiment enhance, making Pfizer a coiled spring at its present worth

So, what does this all imply? There’s an argument that Pfizer’s inventory may face a lift in sentiment if the darkish clouds (tariffs and political strain) filter out, permitting traders to refocus on Pfizer’s progress in oncology and specialty medicine.

At the moment, Pfizer trades at simply 8 instances the midpoint of its 2025 earnings steering. That valuation resembles an organization on the verge of going below, not one that might develop at a high-single-digit tempo over the approaching years. Even when the valuation stays the identical, Pfizer wants little or no progress to generate double-digit funding returns as a result of the dividend begins you off at over 7%.

If issues do go properly and Wall Avenue warms as much as Pfizer, the inventory may produce some critically outsized returns from a profitable trifecta of:

1. A 7.3% dividend
2. Potential high-single-digit progress
3. A valuation that might soar with some optimistic sentiment

It makes Pfizer a incredible alternative for income-focused traders, in addition to cut price hunters on the lookout for some upside in a market already buying and selling at all-time highs, chugging towards 2026.